Topics
News
CME/CE
Editorial Advisory Board
Partnerships
Biochemotherapy Gets Thumb's Down
Chicago - The promise of biochemotherapy for stage IV malignant melanoma has not held up to scrutiny, and the value of this form of treatment seems nil, according to recent discouraging findings from major phase III clinical trials.
Related Videos
Related Content
